Hypothyroidism and dyslipidemia: Modern concepts and approaches

被引：91

作者：

Pearce E.N. ^{[1
]}

机构：

[1] Boston University Medical Center, Boston, MA 02118

来源：

Current Cardiology Reports | 2004年 / 6卷 / 6期

关键词：

Thyroid Hormone; Hypothyroidism; Cholesteryl Ester Transfer Protein; Thyroid Dysfunction; Subclinical Hypothyroidism;

D O I：

10.1007/s11886-004-0054-3

中图分类号：

学科分类号：

摘要：

Subclinical and overt hypothyroidism are relatively common disorders in the general population. Thyroid hormone is known to play a role in regulating the synthesis, metabolism, and mobilization of lipids. In patients with overt hypothyroidism there is an increase in serum total cholesterol, low-density lipoprotein (LDL) cholesterol, apolipoprotein B, lipoprotein(a) [Lp(a)] levels, and possibly triglyceride levels. The effects of subclinical hypothyroidism on serum lipid values are less clear. The preponderance of evidence suggests that total cholesterol, LDL cholesterol, and possibly triglycerides are increased in patients with subclinical hypothyroidism, whereas high-density lipoprotein (HDL) cholesterol and Lp(a) remain unchanged. Most lipid abnormalities in patients with overt hypothyroidism will resolve with thyroid hormone replacement therapy. However, clinical trials to date have not shown a beneficial effect of thyroid hormone treatment on serum lipid levels in patients with subclinical hypothyroidism. The lipid-altering effects of thyroid hormone make it an appealing target for drug development. The development of specifically targeted thyroid hormone analogues that could potentially treat hyperlipidemia without causing systemic thyrotoxicosis is currently ongoing. Copyright © 2004 by Current Science Inc.

引用

页码：451 / 456

页数：5

共 49 条

[1]

Mason R.L., Hunt H.M., Hurxthal L., Blood cholesterol values in hyperthyroidism and hypothyroidism, N. Engl. J. Med., 203, pp. 1273-1278, (1930)

[2]

Hollowell J.G., Staehling N.W., Flanders W.D., Et al., Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III), J. Clin. Endocrinol. Metab., 87, pp. 489-499, (2002)

[3]

Sawin C.T., Castelli W.P., Hershman J.M., Et al., The aging thyroid: Thyroid deficiency and the Framingham Study, Arch. Intern. Med., 145, pp. 1386-1388, (1985)

[4]

Vanderpump M.J.P., Tunbridge W.M.G., French J.M., Et al., The incidence of thyroid disorders in the community: A twenty-year follow-up of the Whickham Survey, Clin. Endocrinol., 43, pp. 55-68, (1995)

[5]

Choi J.W., Choi H.S., The regulatory effects of thyroid hormone on the activity of 3-hydroxy-3-methylglutaryl coemzyme A reductase, Endocr. Res., 26, pp. 1-21, (2000)

[6]

Shin D.J., Osborne T.F., Thyroid hormone regulation and cholesterol metabolism are connected through sterol regulatory element-binding protein-2 (SREBP-2), J. Biol. Chem., 278, pp. 34114-34118, (2003)

[7]

Tan K.C.B., Shiu S.W.M., Kung A.W.C., Plasma cholsteryl ester transfer protein activity in hyper- and hypothyroidism, J. Clin. Endocrinol. Metab., 83, pp. 140-143, (1998)

[8]

Lam K.S., Chan M.K., Yeung R.T., High-density lipoprotein cholesterol, hepatic lipase and lipoprotein lipase activities in thyroid dysfunction - Effects of treatment, Q. J. Med., 59, pp. 513-521, (1986)

[9]

Pauletzki J., Stellaard F., Paumgartner G., Bile acid metabolism in human hyperthyroidism, Hepatology, 9, pp. 852-855, (1989)

[10]

Boberg J., Dahlberg P.A., Vessby B., Lithell H., Serum lipoprotein and apolipoprotein concentrations in patients with hyperthyroidism and the effect of treatment with carbimazole, Acta Med. Scand., 215, pp. 453-459, (1984)

← 1 2 3 4 5 →